Business
Appointment of Joint Corporate Broker
Appointment of Joint Corporate Broker.
About this update from Fortis Frontier Plc
[{"type":"text","content":"\n \nRNS Number : 2486W Concepta PLC 13 November 2017 \n\n13 November 2017 \n \nConcepta plc \n(\"Concepta\" or the \"Company\") \nAppointment of Joint Corporate Broker\nThe Board of Concepta plc (AIM: CPT), the pioneering UK healthcare company and developer of a proprietary platform and suite of products targeted at the personalised mobile health market with a primary focus on women's fertility and specifically unexplained infertility, is pleased to announce the appointment of Novum Securities Limited to act as the Company's Joint Corporate Broker alongside Beaufort Securities Limited, with immediate effect.\nEnquiries:\nThe Company\nErik Henau\nCEO\nTel +44 (0) 1234 866601\n \nSPARK Advisory Partners Limited (Nomad)\nNeil Baldwin / Mark Brady\nTel: +44 (0)20 368 3550\n \nBeaufort Securities Limited (Joint Broker)\nJon Belliss\nTel: +44 (0)20 7382 8300\n \nNovum Securities (Joint Broker)\nColin Rowbury\n+44 (0) 20 7399 9400\n \nYellow Jersey (Financial PR)\nGeorgia Colkin / Joe Burgess / Katie Bairsto\nTel: +44 (0) 776 932 5254\n \nAbout Concepta Plc:\nConcepta plc is a pioneering UK healthcare company that has developed a proprietary platform and products targeted at the personalised mobile health market with a primary focus on women's fertility and specifically unexplained infertility*.\nFounded in 2013, Concepta has developed a revolutionary flagship product 'MyLotus' for home self-testing that helps women with unexplained infertility to conceive. \nMyLotus is the only consumer product which allows both quantitative and qualitative measurements of measurement of a woman's personal hCG and LH hormone levels in an easy to use home test to facilitate higher conception rates and early diagnosis of any fertility problems. Competitor products currently only allow qualitative measurement and are based on the 'average woman'. \nConcepta has a defined route to market for its new 'My Lotus' product with Regulatory approvals for launch in China in place for 2016 and CE-Marking for UK and Europe to follow in 2018 where the revenue potential of the Chinese and EU infertility market is worth c.£600m per annum for the company.\n*Unexplained infertility refers to women that have been unable to conceive after 6 months of trying. This highly motivated target group of co...